Keyword: Opana ER


8. Endo International

Endo didn’t even make it to the top 20 generics companies by 2014 revenue. Then the merger with Par happened, but the joy didn’t last long; its stock started tumbling down like an avalanche, and its final 2016 financial result of $2.56 billion was less than 60% of its original expectation.